Estrella Immunopharma, Inc. (NASDAQ:ESLA) Sees Significant Decline in Short Interest

Estrella Immunopharma, Inc. (NASDAQ:ESLA) saw a large decline in short interest in the month of April. As of April 15th, there was short interest totalling 1,900 shares, a decline of 88.8% from the March 31st total of 17,000 shares. Currently, 0.0% of the company’s shares are sold short. Based on an average daily trading volume, of 83,900 shares, the short-interest ratio is currently 0.0 days.

Analyst Upgrades and Downgrades

Separately, D. Boral Capital initiated coverage on shares of Estrella Immunopharma in a research note on Tuesday, February 18th. They set a “buy” rating and a $16.00 price target for the company.

Institutional Trading of Estrella Immunopharma

A hedge fund recently raised its stake in Estrella Immunopharma stock. Geode Capital Management LLC lifted its holdings in Estrella Immunopharma, Inc. (NASDAQ:ESLA) by 22.0% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 93,418 shares of the company’s stock after purchasing an additional 16,862 shares during the period. Geode Capital Management LLC owned about 0.26% of Estrella Immunopharma worth $106,000 at the end of the most recent quarter. Institutional investors and hedge funds own 0.35% of the company’s stock.

Estrella Immunopharma Stock Performance

NASDAQ ESLA traded up $0.07 on Monday, reaching $1.07. 33,691 shares of the stock traded hands, compared to its average volume of 84,733. Estrella Immunopharma has a 12 month low of $0.63 and a 12 month high of $3.23. The company has a market cap of $38.59 million, a price-to-earnings ratio of -4.10 and a beta of 0.44. The company has a fifty day moving average price of $0.97 and a 200-day moving average price of $1.03.

About Estrella Immunopharma

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia.